News

Hosted on MSN2m
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna
Novo Nordisk (NVO) announced a new $2.2 billion deal with San ... to competitor Eli Lilly's (LLY) Zepbound. Novo also ...